The global nasal allergy treatment market enjoys a valuation of US$ 6.6 Billion in 2022, and it is further projected to expand at a CAGR of 6.7% over the forecasted years. According to a recent study by Future Market Insights, allergic rhinitis by disease is leading the market with a share of about 65.8% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 6.6 Billion |
| Market Value 2033 | US$ 13.3 Billion |
| CAGR 2023 to 2033 | 6.7% |
| Market Share of Top 5 Countries | 62.1% |
| Key Market Players | Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma , ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca |
Nasal allergy, or allergic rhinitis (AR), a non-infectious inflammatory disease of the nasal mucosa following exposure to inhaled allergens in atopic patients, is mediated by IgE and involves a number of immune cells and cytokines. The currently available treatment options have increased due to a growing number of manufacturers identifying allergy as an area of interest and also with the help of a research and development team they are bringing in new innovative treatment and therapy options to the market. Although we are in the second wave of allergic diseases there is still a persistent amount of the population who suffer from nasal allergies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 6.7% between 2023 and 2033, owing to the rising prevalence of allergic diseases.
The global market holds around 32.6% share of the overall global allergy treatment market with a value of around US$ 20.2 Billion, in 2022.
The market is expanding as a result increase in the patient pool suffering from allergies. In fact, it is anticipated that the need for nasal allergy treatments would rise in the coming years due to the patient’s comfort and ease as it reduces inflammation, and remove congestion. The incidence rate and prevalence rate of allergic rhinitis are growing rapidly owing to which the demand for available treatments is expected to increase over the forecast period.
Some of the most popular therapies for nasal allergies are antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists. Antihistamines rule the market, as it is one of the highly prescribed and adopted drugs for the treatment of allergies with or without prescription.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 13.3 billion during the year 2033.
Globally, the prevalence of hay fever/allergic rhinitis was registered at ~35%, which is gaining the attraction of manufacturers to develop a specific treatment for this indication. This creates an enormous opportunity for the manufacturer to explore the nasal allergy treatment market. The life science industry has set foot into the pharmaceutical industry giving rise to multiple biopharma companies that have proven technology and advanced treatment options that are exclusive and received approval, this gives healthcare specialists to rely upon these new treatment options.
For instance, the main method for treating people with sensitivities to aeroallergens is subcutaneous immunotherapy (SCIT). Subcutaneous immunotherapy (SCIT), a revolutionary treatment for allergic illnesses, reduces discomfort while modifying allergic disease by concentrating on the underlying immunological mechanism. In numerous well-controlled clinical trials, its effectiveness and safety have been proven in the treatment of allergies, allergic rhinitis/rhinoconjunctivitis, asthma, and hypersensitivity to stinging insects.
Overall, it is anticipated that the market for nasal allergy treatments will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.
Principal Consultant
The market is experiencing a decline due to the adverse effects associated with allergy shots and tablets.
Along with that, patients can experience minor effects such as redness or swelling at the injection site or effects on the entire body or particular body system. Along with that, rarely, a serious systemic reaction called anaphylaxis can develop.
In a few cases, people can experience systematic reactions such as hives, nasal congestion, watery eyes, and sneezing. More severe reactions may include wheezing or chest tightness and throat swelling. Rarely, allergy treatments can cause anaphylaxis, a potentially fatal reaction. It may result in low blood pressure and respiratory difficulties. An allergy shot can sometimes cause a significant reaction in a person. The majority of these can happen within 30 minutes of the injection.
The side effects associated with the treatment may hinder the market growth.
The USA dominates the North American region with a total market share of around 92.4% in 2022 and is expected to continue to maintain consistent growth over the entire projected period with a CAGR of 5.8%. The main drivers of nasal allergy prevalence in the United States include environmental factors such as air pollution, climate change, and exposure to allergens such as pollen and dust mites.
Allergies are the sixth most common chronic ailment in the United States, according to the American College of Allergy, Asthma & Immunology, with a cost of more than $18 billion annually. Each year, more than 50 million Americans experience allergic reactions. The frequency of AR was 19.9%, according to a recent large retrospective cohort study by Frontiers Media S.A. in the year 2023. According to the National Health Interview Survey done by the Centers for Disease Control and Prevention in 2018, 19.2 million adults in the US had hay fever (allergic rhinitis) in the previous 12 months.
Since the prevalence is high the manufacturer finds it lucrative to regulate in such a market, therefore this factor influences the nasal allergy treatment market in the most favorable manner in the USA market.
China has a market share of 65.8% in the East Asia nasal allergy treatment market in 2022. Disease progression can be retarded by taking precautions such as diagnostic tests which include the provocation test, specific IgG4 test, tIgE test, and multiple other specific tests that can lead to successful treatment outcomes. China is focusing on improving its diagnosis to pace up into the global market.
For the prevention and treatment of allergic disorders, allergen detection is essential. Although China's technology is now lacking, many of the diagnostic gaps will soon be filled thanks to the development of new microparticle- and array-based methods.
To assist allergists and laboratory personnel in improving the diagnostic standard and directing the treatment of allergic illnesses for the benefit of patients and the market as a whole, this consensus summarizes the existing in vivo and in vitro diagnostic procedures for allergens.
Germany holds a market share of 29.8% in 2022 in the European nasal allergy treatment market, owing to the presence of many established players in European countries.
Bencard Allergie, the German division of Allergy Therapeutics in the United Kingdom, which creates allergy vaccinations, was referenced by Labiotech UG in June 2022. The first allergoids for allergen-specific immunotherapies were marketed by a German business. With the use of virus-like particles, Allergy Therapeutics, and its affiliates are developing a novel method for allergy immunotherapy. Bencard appears to be in a strong position despite its opponents. According to a recent report from Allergy Therapeutics, Bencard contributes 60% of the company's revenues in Germany, which is where sales are growing the fastest.
Germany is strengthening its manufacturing and development of novel drugs which will positively grow the market in the future.
India holds a share of around 48.6% in the South Asia market in 2022.
India has one of the highest levels of pollution, which is largely brought on by the use of mosquito coils and incense sticks indoors, and by outdoor, biomass, fossil fuels, and vehicle exhausts. According to Elsevier Inc., there are an estimated 37.5 million instances of asthma in India, and recent studies have indicated that the frequency of allergic rhinitis and asthma would rise in 2020.
Although India's prevalence rates are generally lower than those of high-income nations, there are still several million instances of the disease overall, according to various estimates. Indian manufacturers must therefore increase their supply of treatment drugs in order to handle such a sizable patient population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Allergic rhinitis is expected to give high growth at a CAGR of 6.4% between 2023 and 2033. As per American Academy of Allergy Asthma and Immunology, 2022, allergic rhinitis affects almost 10-30% of the population worldwide. Additionally, sensitization to foreign proteins present in the environment affects upto 40% of the global population. In the geriatric population, rhinitis is less commonly allergic in nature. Hence the prevalence contributes to the global shares.
Tablets/Capsules are mostly favored by patients suffering from allergies. It has a market share of 37.1% in the global market in 2022.
The most popular sort of pill is a tablet. They encourage market growth since they are an affordable, secure, and efficient method of delivering oral medications. Tablets and capsules are frequently used by makers and formulators of drug products as a dosage form that is affordable.
OTC has a market share of 76.3% in the global market in 2022. OTC medications are easier for customers to obtain because they are readily available and may be bought without a prescription. People aren't obliged to wait for medications to be filled or schedule appointments with doctors, which saves time and money. Because OTC drugs are typically less expensive than prescription drugs, more people can afford them.
Oral route of administration is mostly preferred by patients. It has a market share of 36.6% in the global market in 2022.
Patients can take oral medications at home without the need for medical supervision because they are simple to administer. Patients who need long-term treatment for chronic diseases would especially benefit from this. Drugs used orally are frequently less expensive than medications taken orally or intravenously, which require more specialized equipment and medical supervision.
Antihistamines have a market share of 46.0% in the global market in 2022. Since histamine, a substance secreted by the body in response to an allergen is blocked by antihistamines, they are frequently given for allergies. Sneezing, itching, and runny nose are examples of common allergic reaction symptoms that are brought on by histamine. A variety of allergic reactions, including as hay fever, allergic rhinitis, and hives, can be successfully treated with them.
Hospital pharmacies hold a market share of 35.9% during the year 2022. The main locations where easily accessible licensed and approved medicine is found are hospitals. Hospital pharmacies may greatly enhance patient care by working together with doctors, nurses, and pharmacy teams to supply the appropriate medications and supplies in accordance with treatment procedures. The assurance of better patient outcomes aids hospitals in exceeding patient satisfaction targets. The segment is anticipated to grow at a profitable pace over the forecast period because of the comprehensive care provided in hospital settings.
Increase in number of pipeline products and approval by the regulatory bodies, along with merger and acquisition by key players in different regions, are key differentiating strategies that nasal allergy treatment manufacturers are adopting.
Similarly, recent developments related to companies manufacturing nasal allergy treatment drugs have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Disease Type, Form, Prescription Type, Route of Administration, Treatment, Distribution Channel and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The growth potential of the power nibbler market is 6.7% through 2033.
Adverse effect of tablets is likely to limit market growth.
North America is likely to capture a CAGR of 5.8% in 2023.
The United States is estimated as the fastest-growing country.
Allergic rhinitis segment is leading the global market in 2023.
1. Executive Summary | Nasal Allergy Treatment Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Disease Epidemiology 4.1.1. Prevalence Population 4.1.2. Diagnosed Prevalence Cases 4.1.3. Gender Specific Cases 4.1.4. Severity Specific Cases 4.2. Annual Patient Volume of Disease Type for Key Countries 4.3. Regulatory Landscape 4.4. Patient Pool Suffering from Allergy 4.5. Patient Treatment Journey 4.6. Pipeline Assessment 4.7. PESTLE Analysis 4.8. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Life Expectancy Outlook 5.1.4. Pharmaceutical Spending 5.1.5. Global Allergy Treatment Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increase Prevalence of Allergy Rhinitis 5.2.2. Diagnostic Rate (%) 5.2.3. Treatment Seeking Rate (%) 5.2.4. Cases treated with Nasal Allergies 5.2.5. Overall Cost of Treatment 5.2.6. Recent Advancements In Technology 5.2.7. Regulatory Framework 5.2.8. Key Strategic Developments By Market Players 5.2.9. Adverse Effects May Impact the Market Growth 5.2.10. Growing Investment in Healthcare Sector 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. COVID-19 Crisis – Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Disease Type 6.1.2. Revenue By Form 6.1.3. Revenue By Prescription Type 6.1.4. Revenue By Route of Administration 6.1.5. Revenue By Treatment 6.1.6. Revenue By Distribution Channel 6.1.7. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis, By Disease Type, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 8.3.1. Allergic Rhinitis 8.3.2. Seasonal Allergic Rhinitis 8.3.3. Perennial Allergic Rhinitis 8.3.4. Non-Allergic Rhinitis 8.3.5. Infectious Rhinitis 8.4. Market Attractiveness Analysis By Disease Type 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Form 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Form, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Form, 2023 to 2033 9.3.1. Tablets/Capsules 9.3.2. Liquid 9.3.3. Creams & Lotions 9.3.4. Drops 9.3.5. Spray 9.4. Market Attractiveness Analysis By Form 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Prescription Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Prescription Type, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Prescription Type, 2023 to 2033 10.3.1. OTC 10.3.2. Prescription based 10.4. Market Attractiveness Analysis By Prescription Type 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 11.3.1. Oral 11.3.2. Intranasal 11.3.3. Sublingual 11.3.4. Sub Cutaneous 11.3.5. Intravenous 11.4. Market Attractiveness Analysis By Route of Administration 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis, By Treatment, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 12.3.1. Antihistamines 12.3.2. Decongestants 12.3.3. Nasal Corticosteroids 12.3.4. Allergen Immunotherapy 12.3.5. LeUnited kingdomotriene Receptor Antagonists 12.4. Market Attractiveness Analysis By Treatment 13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 13.3.1. Hospital Pharmacies 13.3.2. Supermarkets/Hypermarkets 13.3.3. Online Pharmacies 13.3.4. Retail Pharmacies 13.3.5. Specialty Clinics 13.3.6. Others 13.4. Market Attractiveness Analysis By Distribution Channel 14. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. East Asia 14.3.5. South Asia 14.3.6. Oceania 14.3.7. Middle East and Africa (MEA) 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Disease Type 15.3.3. By Form 15.3.4. By Prescription Type 15.3.5. By Route of Administration 15.3.6. By Treatment 15.3.7. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Disease Type 15.4.3. By Form 15.4.4. By Prescription Type 15.4.5. By Route of Administration 15.4.6. By Treatment 15.4.7. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. USA Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Disease Type 15.8.1.2.2. By Form 15.8.1.2.3. By Prescription Type 15.8.1.2.4. By Route of Administration 15.8.1.2.5. By Treatment 15.8.1.2.6. By Distribution Channel 15.8.2. Canada Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Disease Type 15.8.2.2.2. By Form 15.8.2.2.3. By Prescription Type 15.8.2.2.4. By Route of Administration 15.8.2.2.5. By Treatment 15.8.2.2.6. By Distribution Channel 16. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Mexico 16.3.1.2. Brazil 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Disease Type 16.3.3. By Form 16.3.4. By Prescription Type 16.3.5. By Route of Administration 16.3.6. By Treatment 16.3.7. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Disease Type 16.4.3. By Form 16.4.4. By Prescription Type 16.4.5. By Route of Administration 16.4.6. By Treatment 16.4.7. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Mexico Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Disease Type 16.8.1.2.2. By Form 16.8.1.2.3. By Prescription Type 16.8.1.2.4. By Route of Administration 16.8.1.2.5. By Treatment 16.8.1.2.6. By Distribution Channel 16.8.2. Brazil Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Disease Type 16.8.2.2.2. By Form 16.8.2.2.3. By Prescription Type 16.8.2.2.4. By Route of Administration 16.8.2.2.5. By Treatment 16.8.2.2.6. By Distribution Channel 16.8.3. Argentina Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Disease Type 16.8.3.2.2. By Form 16.8.3.2.3. By Prescription Type 16.8.3.2.4. By Route of Administration 16.8.3.2.5. By Treatment 16.8.3.2.6. By Distribution Channel 17. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. United kingdom 17.3.1.2. Germany 17.3.1.3. France 17.3.1.4. Italy 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Russia 17.3.1.8. Nordics 17.3.1.9. Rest of Europe 17.3.2. By Disease Type 17.3.3. By Form 17.3.4. By Prescription Type 17.3.5. By Route of Administration 17.3.6. By Treatment 17.3.7. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Disease Type 17.4.3. By Form 17.4.4. By Prescription Type 17.4.5. By Route of Administration 17.4.6. By Treatment 17.4.7. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. U.K. Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Disease Type 17.8.1.2.2. By Form 17.8.1.2.3. By Prescription Type 17.8.1.2.4. By Route of Administration 17.8.1.2.5. By Treatment 17.8.1.2.6. By Distribution Channel 17.8.2. Germany Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Disease Type 17.8.2.2.2. By Form 17.8.2.2.3. By Prescription Type 17.8.2.2.4. By Route of Administration 17.8.2.2.5. By Treatment 17.8.2.2.6. By Distribution Channel 17.8.3. France Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Disease Type 17.8.3.2.2. By Form 17.8.3.2.3. By Prescription Type 17.8.3.2.4. By Route of Administration 17.8.3.2.5. By Treatment 17.8.3.2.6. By Distribution Channel 17.8.4. Italy Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Disease Type 17.8.4.2.2. By Form 17.8.4.2.3. By Prescription Type 17.8.4.2.4. By Route of Administration 17.8.4.2.5. By Treatment 17.8.4.2.6. By Distribution Channel 17.8.5. Spain Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Disease Type 17.8.5.2.2. By Form 17.8.5.2.3. By Prescription Type 17.8.5.2.4. By Route of Administration 17.8.5.2.5. By Treatment 17.8.5.2.6. By Distribution Channel 17.8.6. BENELUX Market Analysis 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Disease Type 17.8.6.2.2. By Form 17.8.6.2.3. By Prescription Type 17.8.6.2.4. By Route of Administration 17.8.6.2.5. By Treatment 17.8.6.2.6. By Distribution Channel 17.8.7. Russia Market Analysis 17.8.7.1. Introduction 17.8.7.2. Market Analysis and Forecast by Market Taxonomy 17.8.7.2.1. By Disease Type 17.8.7.2.2. By Form 17.8.7.2.3. By Prescription Type 17.8.7.2.4. By Route of Administration 17.8.7.2.5. By Treatment 17.8.7.2.6. By Distribution Channel 17.8.8. Nordics Market Analysis 17.8.8.1. Introduction 17.8.8.2. Market Analysis and Forecast by Market Taxonomy 17.8.8.2.1. By Disease Type 17.8.8.2.2. By Form 17.8.8.2.3. By Prescription Type 17.8.8.2.4. By Route of Administration 17.8.8.2.5. By Treatment 17.8.8.2.6. By Distribution Channel 18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Disease Type 18.3.3. By Form 18.3.4. By Prescription Type 18.3.5. By Route of Administration 18.3.6. By Treatment 18.3.7. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Disease Type 18.4.3. By Form 18.4.4. By Prescription Type 18.4.5. By Route of Administration 18.4.6. By Treatment 18.4.7. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. China Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Disease Type 18.8.1.2.2. By Form 18.8.1.2.3. By Prescription Type 18.8.1.2.4. By Route of Administration 18.8.1.2.5. By Treatment 18.8.1.2.6. By Distribution Channel 18.8.2. Japan Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Disease Type 18.8.2.2.2. By Form 18.8.2.2.3. By Prescription Type 18.8.2.2.4. By Route of Administration 18.8.2.2.5. By Treatment 18.8.2.2.6. By Distribution Channel 18.8.3. South Korea Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Disease Type 18.8.3.2.2. By Form 18.8.3.2.3. By Prescription Type 18.8.3.2.4. By Route of Administration 18.8.3.2.5. By Treatment 18.8.3.2.6. By Distribution Channel 19. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. India 19.3.1.2. Malaysia 19.3.1.3. Thailand 19.3.1.4. Indonesia 19.3.1.5. Philippines 19.3.1.6. Vietnam 19.3.1.7. Rest of South Asia 19.3.2. By Disease Type 19.3.3. By Form 19.3.4. By Prescription Type 19.3.5. By Route of Administration 19.3.6. By Treatment 19.3.7. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Disease Type 19.4.3. By Form 19.4.4. By Prescription Type 19.4.5. By Route of Administration 19.4.6. By Treatment 19.4.7. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. India Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Disease Type 19.8.1.2.2. By Form 19.8.1.2.3. By Prescription Type 19.8.1.2.4. By Route of Administration 19.8.1.2.5. By Treatment 19.8.1.2.6. By Distribution Channel 19.8.2. Malaysia Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Disease Type 19.8.2.2.2. By Form 19.8.2.2.3. By Prescription Type 19.8.2.2.4. By Route of Administration 19.8.2.2.5. By Treatment 19.8.2.2.6. By Distribution Channel 19.8.3. Thailand Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Disease Type 19.8.3.2.2. By Form 19.8.3.2.3. By Prescription Type 19.8.3.2.4. By Route of Administration 19.8.3.2.5. By Treatment 19.8.3.2.6. By Distribution Channel 19.8.4. Indonesia Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Disease Type 19.8.4.2.2. By Form 19.8.4.2.3. By Prescription Type 19.8.4.2.4. By Route of Administration 19.8.4.2.5. By Treatment 19.8.4.2.6. By Distribution Channel 19.8.5. Philippines Market Analysis 19.8.5.1. Introduction 19.8.5.2. Market Analysis and Forecast by Market Taxonomy 19.8.5.2.1. By Disease Type 19.8.5.2.2. By Form 19.8.5.2.3. By Prescription Type 19.8.5.2.4. By Route of Administration 19.8.5.2.5. By Treatment 19.8.5.2.6. By Distribution Channel 19.8.6. Vietnam Market Analysis 19.8.6.1. Introduction 19.8.6.2. Market Analysis and Forecast by Market Taxonomy 19.8.6.2.1. By Disease Type 19.8.6.2.2. By Form 19.8.6.2.3. By Prescription Type 19.8.6.2.4. By Route of Administration 19.8.6.2.5. By Treatment 19.8.6.2.6. By Distribution Channel 20. Oceania Market 2018 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Disease Type 20.3.3. By Form 20.3.4. By Prescription Type 20.3.5. By Route of Administration 20.3.6. By Treatment 20.3.7. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Disease Type 20.4.3. By Form 20.4.4. By Prescription Type 20.4.5. By Route of Administration 20.4.6. By Treatment 20.4.7. By Distribution Channel 20.5. Market Trends 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 20.8. Country Level Analysis & Forecast 20.8.1. Australia Market Analysis 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Disease Type 20.8.1.2.2. By Form 20.8.1.2.3. By Prescription Type 20.8.1.2.4. By Route of Administration 20.8.1.2.5. By Treatment 20.8.1.2.6. By Distribution Channel 20.8.2. New Zealand Market Analysis 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Disease Type 20.8.2.2.2. By Form 20.8.2.2.3. By Prescription Type 20.8.2.2.4. By Route of Administration 20.8.2.2.5. By Treatment 20.8.2.2.6. By Distribution Channel 21. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 21.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Türkiye 21.3.1.3. South Africa 21.3.1.4. Israel 21.3.1.5. North Africa 21.3.1.6. Rest of Middle East and Africa 21.3.2. By Disease Type 21.3.3. By Form 21.3.4. By Prescription Type 21.3.5. By Route of Administration 21.3.6. By Treatment 21.3.7. By Distribution Channel 21.4. Market Attractiveness Analysis 21.4.1. By Country 21.4.2. By Disease Type 21.4.3. By Form 21.4.4. By Prescription Type 21.4.5. By Route of Administration 21.4.6. By Treatment 21.4.7. By Distribution Channel 21.5. Market Trends 21.6. Key Market Participants - Intensity Mapping 21.7. Drivers and Restraints - Impact Analysis 21.8. Country Level Analysis & Forecast 21.8.1. GCC Countries Market Analysis 21.8.1.1. Introduction 21.8.1.2. Market Analysis and Forecast by Market Taxonomy 21.8.1.2.1. By Disease Type 21.8.1.2.2. By Form 21.8.1.2.3. By Prescription Type 21.8.1.2.4. By Route of Administration 21.8.1.2.5. By Treatment 21.8.1.2.6. By Distribution Channel 21.8.2. Türkiye Market Analysis 21.8.2.1. Introduction 21.8.2.2. Market Analysis and Forecast by Market Taxonomy 21.8.2.2.1. By Disease Type 21.8.2.2.2. By Form 21.8.2.2.3. By Prescription Type 21.8.2.2.4. By Route of Administration 21.8.2.2.5. By Treatment 21.8.2.2.6. By Distribution Channel 21.8.3. South Africa Market Analysis 21.8.3.1. Introduction 21.8.3.2. Market Analysis and Forecast by Market Taxonomy 21.8.3.2.1. By Disease Type 21.8.3.2.2. By Form 21.8.3.2.3. By Prescription Type 21.8.3.2.4. By Route of Administration 21.8.3.2.5. By Treatment 21.8.3.2.6. By Distribution Channel 21.8.4. Israel Market Analysis 21.8.4.1. Introduction 21.8.4.2. Market Analysis and Forecast by Market Taxonomy 21.8.4.2.1. By Disease Type 21.8.4.2.2. By Form 21.8.4.2.3. By Prescription Type 21.8.4.2.4. By Route of Administration 21.8.4.2.5. By Treatment 21.8.4.2.6. By Distribution Channel 21.8.5. North Africa Market Analysis 21.8.5.1. Introduction 21.8.5.2. Market Analysis and Forecast by Market Taxonomy 21.8.5.2.1. By Disease Type 21.8.5.2.2. By Form 21.8.5.2.3. By Prescription Type 21.8.5.2.4. By Route of Administration 21.8.5.2.5. By Treatment 21.8.5.2.6. By Distribution Channel 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players 22.3. Market Presence Analysis 23. Competition Analysis 23.1. Competition Dashboard 23.2. Key Development Analysis 23.3. Branding and Promotional Strategies, by Manufacturers 23.4. Competition Deep Dive 23.4.1. Merck KGaA 23.4.1.1. Overview 23.4.1.2. Product Portfolio 23.4.1.3. Key Financials 23.4.1.4. SWOT Analysis 23.4.1.5. Key Developments 23.4.1.6. Sales Footprint 23.4.1.7. Strategy Overview 23.4.1.7.1. Marketing Strategies 23.4.1.7.2. Product Strategies 23.4.1.7.3. Channel Strategies 23.4.2. Johnson & Johnson 23.4.2.1. Overview 23.4.2.2. Product Portfolio 23.4.2.3. Key Financials 23.4.2.4. SWOT Analysis 23.4.2.5. Key Developments 23.4.2.6. Sales Footprint 23.4.2.7. Strategy Overview 23.4.2.7.1. Marketing Strategies 23.4.2.7.2. Product Strategies 23.4.2.7.3. Channel Strategies 23.4.3. Allergopharma 23.4.3.1. Overview 23.4.3.2. Product Portfolio 23.4.3.3. Key Financials 23.4.3.4. SWOT Analysis 23.4.3.5. Key Developments 23.4.3.6. Sales Footprint 23.4.3.7. Strategy Overview 23.4.3.7.1. Marketing Strategies 23.4.3.7.2. Product Strategies 23.4.3.7.3. Channel Strategies 23.4.4. Sanofi SA 23.4.4.1. Overview 23.4.4.2. Product Portfolio 23.4.4.3. Key Financials 23.4.4.4. SWOT Analysis 23.4.4.5. Key Developments 23.4.4.6. Sales Footprint 23.4.4.7. Strategy Overview 23.4.4.7.1. Marketing Strategies 23.4.4.7.2. Product Strategies 23.4.4.7.3. Channel Strategies 23.4.5. McNeil Consumer Healthcare, 23.4.5.1. Overview 23.4.5.2. Product Portfolio 23.4.5.3. Key Financials 23.4.5.4. SWOT Analysis 23.4.5.5. Key Developments 23.4.5.6. Sales Footprint 23.4.5.7. Strategy Overview 23.4.5.7.1. Marketing Strategies 23.4.5.7.2. Product Strategies 23.4.5.7.3. Channel Strategies 23.4.6. Genentech Inc. 23.4.6.1. Overview 23.4.6.2. Product Portfolio 23.4.6.3. Key Financials 23.4.6.4. SWOT Analysis 23.4.6.5. Key Developments 23.4.6.6. Sales Footprint 23.4.6.7. Strategy Overview 23.4.6.7.1. Marketing Strategies 23.4.6.7.2. Product Strategies 23.4.6.7.3. Channel Strategies 23.4.7. GlaxoSmithKline PLC 23.4.7.1. Overview 23.4.7.2. Product Portfolio 23.4.7.3. Key Financials 23.4.7.4. SWOT Analysis 23.4.7.5. Key Developments 23.4.7.6. Sales Footprint 23.4.7.7. Strategy Overview 23.4.7.7.1. Marketing Strategies 23.4.7.7.2. Product Strategies 23.4.7.7.3. Channel Strategies 23.4.8. Leti Pharma, 23.4.8.1. Overview 23.4.8.2. Product Portfolio 23.4.8.3. Key Financials 23.4.8.4. SWOT Analysis 23.4.8.5. Key Developments 23.4.8.6. Sales Footprint 23.4.8.7. Strategy Overview 23.4.8.7.1. Marketing Strategies 23.4.8.7.2. Product Strategies 23.4.8.7.3. Channel Strategies 23.4.9. Alerpharma S.A 23.4.9.1. Overview 23.4.9.2. Product Portfolio 23.4.9.3. Key Financials 23.4.9.4. SWOT Analysis 23.4.9.5. Key Developments 23.4.9.6. Sales Footprint 23.4.9.7. Strategy Overview 23.4.9.7.1. Marketing Strategies 23.4.9.7.2. Product Strategies 23.4.9.7.3. Channel Strategies 23.4.10. Allergan, Inc. 23.4.10.1. Overview 23.4.10.2. Product Portfolio 23.4.10.3. Key Financials 23.4.10.4. SWOT Analysis 23.4.10.5. Key Developments 23.4.10.6. Sales Footprint 23.4.10.7. Strategy Overview 23.4.10.7.1. Marketing Strategies 23.4.10.7.2. Product Strategies 23.4.10.7.3. Channel Strategies 23.4.11. Meda Pharmaceuticals, Inc 23.4.11.1. Overview 23.4.11.2. Product Portfolio 23.4.11.3. Key Financials 23.4.11.4. SWOT Analysis 23.4.11.5. Key Developments 23.4.11.6. Sales Footprint 23.4.11.7. Strategy Overview 23.4.11.7.1. Marketing Strategies 23.4.11.7.2. Product Strategies 23.4.11.7.3. Channel Strategies 23.4.12. Novartis International AG 23.4.12.1. Overview 23.4.12.2. Product Portfolio 23.4.12.3. Key Financials 23.4.12.4. SWOT Analysis 23.4.12.5. Key Developments 23.4.12.6. Sales Footprint 23.4.12.7. Strategy Overview 23.4.12.7.1. Marketing Strategies 23.4.12.7.2. Product Strategies 23.4.12.7.3. Channel Strategies 23.4.13. Bausch Health Companies Inc. 23.4.13.1. Overview 23.4.13.2. Product Portfolio 23.4.13.3. Key Financials 23.4.13.4. SWOT Analysis 23.4.13.5. Key Developments 23.4.13.6. Sales Footprint 23.4.13.7. Strategy Overview 23.4.13.7.1. Marketing Strategies 23.4.13.7.2. Product Strategies 23.4.13.7.3. Channel Strategies 23.4.14. Allergopharma 23.4.14.1. Overview 23.4.14.2. Product Portfolio 23.4.14.3. Key Financials 23.4.14.4. SWOT Analysis 23.4.14.5. Key Developments 23.4.14.6. Sales Footprint 23.4.14.7. Strategy Overview 23.4.14.7.1. Marketing Strategies 23.4.14.7.2. Product Strategies 23.4.14.7.3. Channel Strategies 23.4.15. ALK Abello 23.4.15.1. Overview 23.4.15.2. Product Portfolio 23.4.15.3. Key Financials 23.4.15.4. SWOT Analysis 23.4.15.5. Key Developments 23.4.15.6. Sales Footprint 23.4.15.7. Strategy Overview 23.4.15.7.1. Marketing Strategies 23.4.15.7.2. Product Strategies 23.4.15.7.3. Channel Strategies 23.4.16. Stallergenes Greer 23.4.16.1. Overview 23.4.16.2. Product Portfolio 23.4.16.3. Key Financials 23.4.16.4. SWOT Analysis 23.4.16.5. Key Developments 23.4.16.6. Sales Footprint 23.4.16.7. Strategy Overview 23.4.16.7.1. Marketing Strategies 23.4.16.7.2. Product Strategies 23.4.16.7.3. Channel Strategies 23.4.17. Allergy Therapeutics 23.4.17.1. Overview 23.4.17.2. Product Portfolio 23.4.17.3. Key Financials 23.4.17.4. SWOT Analysis 23.4.17.5. Key Developments 23.4.17.6. Sales Footprint 23.4.17.7. Strategy Overview 23.4.17.7.1. Marketing Strategies 23.4.17.7.2. Product Strategies 23.4.17.7.3. Channel Strategies 23.4.18. Aimmune Therapeutics 23.4.18.1. Overview 23.4.18.2. Product Portfolio 23.4.18.3. Key Financials 23.4.18.4. SWOT Analysis 23.4.18.5. Key Developments 23.4.18.6. Sales Footprint 23.4.18.7. Strategy Overview 23.4.18.7.1. Marketing Strategies 23.4.18.7.2. Product Strategies 23.4.18.7.3. Channel Strategies 23.4.19. Biomay AG 23.4.19.1. Overview 23.4.19.2. Product Portfolio 23.4.19.3. Key Financials 23.4.19.4. SWOT Analysis 23.4.19.5. Key Developments 23.4.19.6. Sales Footprint 23.4.19.7. Strategy Overview 23.4.19.7.1. Marketing Strategies 23.4.19.7.2. Product Strategies 23.4.19.7.3. Channel Strategies 23.4.20. HAL Allergy Group 23.4.20.1. Overview 23.4.20.2. Product Portfolio 23.4.20.3. Key Financials 23.4.20.4. SWOT Analysis 23.4.20.5. Key Developments 23.4.20.6. Sales Footprint 23.4.20.7. Strategy Overview 23.4.20.7.1. Marketing Strategies 23.4.20.7.2. Product Strategies 23.4.20.7.3. Channel Strategies 23.4.21. Bayer 23.4.21.1. Overview 23.4.21.2. Product Portfolio 23.4.21.3. Key Financials 23.4.21.4. SWOT Analysis 23.4.21.5. Key Developments 23.4.21.6. Sales Footprint 23.4.21.7. Strategy Overview 23.4.21.7.1. Marketing Strategies 23.4.21.7.2. Product Strategies 23.4.21.7.3. Channel Strategies 23.4.22. AstraZeneca 23.4.22.1. Overview 23.4.22.2. Product Portfolio 23.4.22.3. Key Financials 23.4.22.4. SWOT Analysis 23.4.22.5. Key Developments 23.4.22.6. Sales Footprint 23.4.22.7. Strategy Overview 23.4.22.7.1. Marketing Strategies 23.4.22.7.2. Product Strategies 23.4.22.7.3. Channel Strategies 24. Assumptions and Acronyms Used 25. Research Methodolog
Explore Healthcare Insights
View Reports
Nasal Allergy Treatment Market
